Exhibit 99.1  Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

| | • | | *GEM103 Phase 2a as a possible add-on therapy for patients with wet AMD at risk for macular atrophy completed enrollment, with six-month data to be shared by year-end* | | --- | --- | --- | --- |

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.